Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIXIR: LCI vs FEV1 in Cystic Fibrosis
NCT02248922Phase 4Terminated
- Sponsor
- Novartis
- Start
- Jan 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa infection, sponsored by Novartis. Primary endpoint: Lung Clearance Index at 4 weeks. Started Jan 2015; status: terminated.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT02248922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02248922.